<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="121278">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01523899</url>
  </required_header>
  <id_info>
    <org_study_id>030927</org_study_id>
    <nct_id>NCT01523899</nct_id>
  </id_info>
  <brief_title>Antimicrobial Stewardship Through MRSA Diagnosis in Emergency Department (ED) Patients With Abscesses</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>George Washington University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>George Washington University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study expands upon pilot data for feasibility since May 2011. The study aims to
      evaluate the effect of rapid test availability on use of targeted spectrum antibiotics for
      non-MRSA abscesses in ambulatory patients in the Emergency Department (ED). The
      multi-institutional study will assess the feasibility of providing the GeneXpert® MRSA/SA
      SSTI assay to the ED and evaluate the impact of delivering the test result to clinicians in
      real-time on patient management decisions regarding the use of antimicrobial agents.
      Patients are randomized to standard culture (control arm) or to the GeneXpert® assay plus
      standard culture.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>antibiotic usage</measure>
    <time_frame>0 days</time_frame>
    <description>antibiotic use (narrow spectrum, broad spectrum, or none) will be recorded at the time of the ED visit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical improvement</measure>
    <time_frame>2 to 7 days</time_frame>
    <description>clinical improvement (decreasing erythema, pain, swelling, drainage, and presence or absence of fever) will be documented at 2-7 day phone follow up and 1 and 3 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">272</enrollment>
  <condition>Cutaneous Abscess</condition>
  <arm_group>
    <arm_group_label>Xpert MRSA/SA SSTI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard culture</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Xpert MRSA/SA SSTI</intervention_name>
    <description>Use of Xpert MRSA/SA SSTI assay</description>
    <arm_group_label>Xpert MRSA/SA SSTI</arm_group_label>
    <arm_group_label>Standard culture</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adults 18 years or older with community onset abscess

        Exclusion Criteria:

          -  previous treatment for same abscess in past 14 days

          -  postoperative infection

          -  inability to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Larissa S May, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The George Washington University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The George Washington University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <lastchanged_date>March 9, 2015</lastchanged_date>
  <firstreceived_date>January 26, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>George Washington University</investigator_affiliation>
    <investigator_full_name>Larissa May</investigator_full_name>
    <investigator_title>Assistant Professor of Emergency Medicine</investigator_title>
  </responsible_party>
  <keyword>SSTI</keyword>
  <keyword>cutaneous abscess</keyword>
  <keyword>boil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Abscess</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
